Michael McCormick was named Chief Executive Officer of Nuwellis, Inc., effective June 30, 2026. As of November 8, 2026, Nuwellis, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 1, 2026 to June 18, 2026, naming 1 appointment and 1 departure (Form 8-K, June 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Nuwellis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Nuwellis, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-01 to 2026-06-18. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Nuwellis, Inc. files it.
Also on the record for Nuwellis, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 18, 2026 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by Orca Capital AG | 7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.7% of the class | 5%+ stakes | Source |
| August 5, 2026 | Stake report, Schedule 13G, by Lind Global Fund III LP | 6.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 7.11% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC | 5.4% of the class | 5%+ stakes | Source |
| November 20, 2024 | Form D, private offering | $3.85M sold | Form D page | Source |
Selling to them or working with them? See who runs Nuwellis, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Nuwellis, Inc. and the records around it.
Nuwellis, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Nuwellis, Inc.
Get an email when Nuwellis, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nuwellis, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nuwellis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nuwellis, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-18 | Out | 2026-06-30 | 8-K, 2026-06-18 | ||
| 2026-06-18 | In | Chief Executive Officer | 2026-06-30 | 8-K, 2026-06-18 | |
| 2026-04-01 | Reported | not named in the filing | 8-K/A, 2026-04-01 |
Who leads Nuwellis, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Michael McCormick, appointed, effective 2026-06-30 (filed 2026-06-18).
New leaders reset buying decisions — get the Full Report on Nuwellis, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Nuwellis, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Nuwellis, Inc.Every change, in the filing's words
Departing: John L. Erb, effective 2026-06-30
On June 16, 2026, Nuwellis, Inc. (the "Company" ) announced that John L. Erb resigned from the Company, effective June 30, 2026 (" Resignation Date ").
Appointed: Michael McCormick, Chief Executive Officer, effective 2026-06-30
Appointment Chief Executive Officer Effective as of June 30, 2026, the Board appointed Michael McCormick as the Company's Chief Executive Officer and President and member of the Company's board of directors.
- Mr. Erb's resignation was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
- Mr. Erb will continue to serve as Chairman of the Company's board of directors (the "Board").
- Mr. McCormick will join the Board as of June 30, 2026.
- Mr. McCormick, age 65, has provided consulting services to the Company since September 2025, including serving as Chief Commercial Officer under a consulting arrangement.
- He previously served as a director of the Company from June 2023 to January 2026.
- Mr. McCormick is a seasoned executive with more than 30 years of experience leading medical device companies and serving on the boards of private and publicly traded life sciences companies.
- Since 2023, Mr. McCormick has served as President and Chief Executive Officer of CorRen Medical, Inc., a private medical technology company focused on improving the diagnosis and management of peripheral artery disease, and where he will transition to Executive Chairman effective June 30, 2026.
- From 2010 to 2023, Mr. McCormick served as Chief Executive Officer of Osprey Medical (ASX: OSP), a commercial-stage medical device company focused on technologies designed to reduce contrast-induced acute kidney injury.
Reported
Copies of their resignation letters were attached as exhibits to the Initial Filing.
- As previously disclosed in the Initial Filing, on March 26, 2026, each of Mika Grasso and Katharyn Field resigned, effective immediately, from the Board.
- On March 31, 2026, each of Katharyn Field and Mika Grasso provided supplemental letters to the Company's Initial Filing (the "Response Letters").
- The Response Letters are attached hereto as Exhibits 17.1 and 17.2, respectively.
- The Company and the continuing members of the Board do not agree with certain statements made by Ms. Field and Mr. Grasso in the Response Letters and believe that the Company's description of the circumstances set forth in the Initial Filing is accurate.
- CAUTIONARY NOTE IN THE INTERESTS OF FULL AND COMPLETE DISCLOSURE, THE RESPONSE LETTERS DELIVERED BY MR.
- FIELD ARE BEING FILED IN EXACTLY THE FORM IN WHICH THEY WERE PROVIDED TO THE COMPANY, WITHOUT REDACTION OR MODIFICATION OF ANY KIND.
- THE COMPANY WISHES TO EMPHASIZE THAT THE PREVIOUSLY FILED RESIGNATION LETTERS AND THE ATTACHED RESPONSE LETTERS REFLECT ONLY THE THOUGHTS AND BELIEFS OF MR.
- FIELD, WHICH MAY OR MAY NOT CORRESPOND WITH THE THOUGHTS AND BELIEFS OF ANY REPRESENTATIVE OF THE COMPANY, AND MANY OF WHICH ARE EXPRESSLY CONTRARY TO THE THOUGHTS AND BELIEFS OF THE COMPANY'S MANAGEMENT AND THE BOARD AND TO THE FACTS RELEVANT TO THE VARIOUS ISSUES.
Tools for this story
Each opens in a new tab, filled in for Nuwellis, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.